Form 4 for EYPT EyePoint, Inc.
Accepted 2024-01-09 00:00:00 ET · period of report 2024-01-05 · accession 0001562180-24-000403 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-09 | 2024-01-06 | EYPT | Paggiarino Dario A. | Chief Medical Off | M - OptEx | $0.00 | +15.3K | 41.0K | +59% | $0 |
| D | 2024-01-09 | 2024-01-06 | EYPT | Paggiarino Dario A. | Chief Medical Off | F - Tax | $20.40 | -4,487 | 36.5K | -11% | -$91.5K |
| D | 2024-01-09 | 2024-01-06 | EYPT | Paggiarino Dario A. | Chief Medical Off | M - OptEx | $0.00 | -15.3K | 30.6K | -33% | $0 |
| DM | 2024-01-09 | 2024-01-05 | EYPT | Paggiarino Dario A. | Chief Medical Off | A - Grant | $0.00 | +63.0K | 42.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-06 | M | A | 15,285 | $0.00 | 40,992 | D | — | — | |
| 2 | Common | Common Stock | 2024-01-06 | F | D | 4,487 | $20.40 | 36,505 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2024-01-06 | M | D | 15,285 | $0.00 | 30,570 | D | $0.00 · — to 2033-06-19 | 15,285 Common Stock | (F4) The restricted stock units vests in three ratable annual installments beginning January 6, 2024. |
| 4 | Derivative | Restricted Stock Units | 2024-01-05 | A | A | 21,000 | $0.00 | 21,000 | D | $0.00 · — to 2034-01-05 | 21,000 Common Stock | (F2) The restricted stock units will vest in three ratable annual installments beginning January 5, 2025. |
| 5 | Derivative | Stock Option (Right to Buy) | 2024-01-05 | A | A | 42,000 | $0.00 | 42,000 | D | $20.40 · — to 2034-01-04 | 42,000 Common Stock | (F3) The option to purchase will vest and become exercisable as follows: 25% at January 5th, 2025 and the remainder ratably, on a monthly basis, over the remaining three years. |